HealthNews Pulse
AstraZeneca's Lung-Cancer Combination Shows Why Biomarkers Matter
A late-stage trial found that combining AstraZeneca's Tagrisso with Hutchmed's Orpathys improved progression-free survival for a specific group of pat…
Read the full pulseContinue in Briflio to read, react, comment, and share.
Sources